Biomednewsbreaks - Heartbeam Inc. (NASDAQ: BEAT) To Present At JP Morgan 2025 Annual Healthcare Conference

(MENAFN- Investor Brand Network) HeartBeam (NASDAQ: BEAT) , a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco. CEO Robert Eno and CFO Timothy Cruickshank will meet with investors and potential partners to discuss the recently FDA-cleared HeartBeam system, the first cable-free, credit card-sized ECG device designed for comprehensive arrhythmia assessment. Combining its patented high-fidelity ECG Technology with AI-driven analysis, HeartBeam aims to provide a longitudinal view of cardiac health, transforming cardiovascular diagnostics and predictive care for millions of patients worldwide.

To view the full press release, visit

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to BEAT are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN23122024000224011066ID1109024546